Key Takeaways
- Swiss Roche AG will acquire 89bio for $14.50 per share, totaling $2.4 billion, with potential additional payments through contingent value rights.
- Pegozafermin, a drug in development for treating MASH, aims to address liver fibrosis and metabolic dysfunction.
- The market for MASH treatments represents a multi-billion-dollar opportunity, with significant patient populations anticipated in the coming years.
Deal Details
Swiss Roche AG has agreed to acquire 89bio for $14.50 per share in cash, amounting to an equity value of $2.4 billion. Shareholders will also receive a non-tradable contingent value right (CVR) worth up to $6.00 per share, potentially increasing the total deal value to $3.5 billion. This represents a 52% premium based on 89bio’s 60-day volume-weighted average price (VWAP) as of September 17, 2025.
Each CVR includes milestone payments that could total up to $1.0 billion:
– $2.00 per share upon the first commercial sale of pegozafermin for F4 MASH cirrhosis, expected by March 2030.
– $1.50 per share when annual net sales reach $3.0 billion globally by December 2033.
– $2.50 per share when annual net sales reach $4.0 billion globally by December 2035.
About Pegozafermin
Pegozafermin is a glycoPEGylated analogue of the fibroblast growth factor 21 (FGF21) currently undergoing Phase III clinical trials for moderate to severe MASH fibrosis (F2 and F3 stages) and cirrhosis (F4 stage). Its dual role combines anti-fibrotic and anti-inflammatory mechanisms while aiming for a favorable safety profile. Roche plans to incorporate pegozafermin into its cardiovascular, renal, and metabolic (CVRM) portfolio, considering future development combinations with incretin therapies.
The drug functions by mimicking FGF21, which helps regulate energy and lipid metabolism. It binds FGF receptors, enhancing fatty acid oxidation and improving insulin sensitivity, thereby aiming to slow the progression of liver fibrosis and associated metabolic disorders.
Competitive Landscape
Multiple companies are actively developing FGF21 analogues. Akero, for instance, is pursuing efruxifermin in Phase III trials. While FGF21 analogues offer notable metabolic benefits and anti-fibrotic effects, they face challenges with injection administration and long-term tolerability. Compared to established incretins, which focus on weight loss and glycemic control, FGF21 analogues may provide more substantial anti-fibrotic outcomes.
Market Potential
MASH is estimated to affect 5–7% of the global adult population, with a significant portion dealing with comorbid conditions like obesity and type 2 diabetes. Projections from IQVIA suggest that around 14 million individuals in the U.S. will have F2–F4 MASH by 2030. Drug sales for MASH treatments across the seven major markets were approximately $802.3 million in 2022, highlighting a substantial growth opportunity as awareness and treatment options escalate. Other pharmaceutical companies are also advancing their candidates in Phase III trials, further intensifying the competition within the MASH treatment space.
The content above is a summary. For more details, see the source article.